1. Home
  2. CVAC

as 12-17-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.

Founded: 2000 Country:
Germany
Germany
Employees: N/A City: N/A
Market Cap: 637.1M IPO Year: 2020
Target Price: $10.00 AVG Volume (30 days): 523.1K
Analyst Decision: Hold Number of Analysts: 3
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.33 EPS Growth: N/A
52 Week Low/High: $2.21 - $5.28 Next Earning Date: 11-12-2024
Revenue: $70,565,734 Revenue Growth: 75.11%
Revenue Growth (this year): 738.59% Revenue Growth (next year): -87.39%

CVAC Daily Stock ML Predictions

Share on Social Networks: